• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Doctors
    • Information
      • Service invoicing
      • Service invoicing for pathologists
    • Clinical trials
      • Lung Cancer Study Group
      • General information
  • Patients
    • General information
      • Driver mutations in lung cancer
      • New immunotherapeutic therapeutic approaches
      • Second Opinion service
      • Molecular Diagnostics
      • New therapeutic approaches from genomic research
    • Clinical trials
      • Lung Cancer Study Group
      • General information
      • What is a clinical trial?
      • Participation in a trial
    • Find doctors nearby
  • The Network
    • Aims
    • Funding
    • Our team
    • Publications
    • Related links
  • Driver mutations
  • Diagnostics
  • Hybrid-capture
  • Fast-track analysis for first-line treatment
Select Page

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J

Journal: JAMA
published: 2017 May 9

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress